SAFETY DATA SHEET



Antibodies Reagent IVD

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name

Part no.

: Antibodies Reagent IVD **8920007**, 8920012, 8920015, 8920016, 8920017, 8920018, 8920022, 8920023, 8920036, 8920043, 8920045, 8920048, 8920049, 8920050, 8920053, 8920054, 8920064, 8920070, 8920084, 8920085, 8920086, 8920100, 8920108, 8920109, 8920119, 8920120, 8920123, 8920130, 8920132, 8920140, 8920144, 8920158, 8920200, 8920216, 8920230, 8920248, 8920249, 8920255, 8920261, 8920262, 8920263, 8920264, 8920265, 8920266, 8920267, 8920268, 8920269, 8920270, 8920271, 8920272, 8920273, 8920274, 8920276, 8920277, 8920278, 8920279, 8920280, 8920282, 8920331, 8920959, 8921013, 8921014, 8921015, 8921016, 8921017, 8921018, 8921019, 8921020, 8921021, 8921022, 8921023, 8921024, 8921025, 8921029, 8921030, 8921031, 8921032, 8921033, 8921034, 8921035, 8921036, 8921037, 8921042, 8921043, 8921044, 8921045, 8929995, 8929996, 8929997, 8929998, 8929999, 8930007, 8930012, 8930015, 8930016, 8930017, 8930018, 8930022, 8930023, 8930036, 8930043, 8930045, 8930048, 8930049, 8930050, 8930053, 8930054, 8930064, 8930084, 8930085, 8930086, 8930108, 8930109, 8930114, 8930119, 8930120, 8930123, 8930130, 8930132, 8930144, 8930158, 8930200, 8930216, 8930230, 8930248, 8930249, 8930261, 8930262, 8930263, 8930264, 8930265, 8930266, 8930267, 8930268, 8930269, 8930270, 8930271, 8930272, 8930273, 8930274, 8930276, 8930277, 8930278, 8930279, 8930280, 8930282, 8930331, 8930959, 8931013, 8931014, 8931015, 8931016, 8931017, 8931018, 8931019, 8931020, 8931021, 8931022, 8931023, 8931024, 8931025, 8931029, 8931030, 8931031, 8931032, 8931033, 8931034, 8931035, 8931036, 8931037, 8931042, 8931043, 8931044, 8931045, 8939995, 8939996, 8939997, 8939998, 8939999, 8921066, 8921067, 8921068, 8920698, 8920185, 8931066, 8931067, 8931068, 8930698, 8930185, 8921054, 8931054, 8921050, 8931050, 8921049, 8931049, 8920037, 8930037, 8920114, 8920702, 8920705, 8920796, 8921051, 8930702, 8930705, 8930796, 8931051, 8920005, 8930005, 8921057, 8931057, 8921061, 8931061, 8920091, 8930091, 8920567, 8930567, 8920092, 8930092, 8920012CE, 8930012CE, 8921017CE, 8931017CE, 8921016CE, 8931016CE, 8921034CE, 8931034CE, 8921025CE, 8931025CE, 8921015CE, 8931015CE, 8921019CE, 8931019CE, 8921020CE, 8931020CE, 8921024CE, 8931024CE, 8921023CE, 8931023CE, 8920045CE, 8930045CE, 8920015CE, 8930015CE, 8920007CE, 8930007CE, 8920016CE, 8930016CE, 8920017CE, 8930017CE, 8920070CE, 8921091CE, 8921014CE, 8931014CE, 8920144CE, 8930144CE, 8920263CE, 8930263CE, 8921033CE, 8931033CE, 8920265CE, 8930265CE, 8921036CE, 8931036CE, 8921049CE, 8931049CE, 8920264CE, 8930264CE, 8921013CE, 8931013CE, 8920216CE, 8930216CE, 8921032CE, 8931032CE, 8920266CE, 8930266CE, 8920268CE, 8930268CE, 8920132CE, 8930132CE, 8921035CE, 8931035CE, 8920037CE, 8930037CE, 8920277CE, 8930277CE, 8920085CE, 8930085CE, 8920086CE, 8930086CE, 8921068CE, 8931068CE, 8921067CE, 8931067CE, 8921066CE, 8931066CE, 8920698CE, 8930698CE, 8920959CE, 8930959CE, 8920269CE, 8930269CE, 8920270CE, 8930270CE, 8920271CE, 8930271CE, 8920278CE, 8930278CE, 8920279CE, 8930279CE, 8921044CE, 8931044CE, 8921045CE, 8931045CE, 8920273CE, 8930273CE, 8920262CE, 8930262CE, 8920123CE, 8930123CE, 8921031CE, 8931031CE, 8920274CE, 8930274CE, 8929988, 8939988, 8929989, 8939989, 8929990, 8939990, 8929991, 8939991, 8929992, 8939992, 8929993, 8939993, 8921073, 8931073, 8920142, 8930142, 8920034, 8930034, 8920046, 8930046,

1.2 Relevant identified uses of the substance or mixture and uses advised against **Identified uses**

8921074, 8931074

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version: 4.2 1/17

SECTION 1: Identification of the substance/mixture and of the company/undertaking

or In Vitro	Diagnostic Use
8920007	APC Mouse anti-human CD19
8920012	CD4/CD8/CD3 mouse anti-human
8920015	PE-Cy7 Mouse anti-human CD19
8920016	FITC Mouse anti-human CD19
8920017	PE Mouse anti-human CD19
8920018	PE Mouse anti-human CD1a
8920022	FITC Mouse anti-human CD2
8920023	PE Mouse anti-human CD2
8920036	PE Mouse anti-human CD7
8920043	FITC Mouse anti-human CD10
8920045	APC Mouse anti-human CD10
8920048	PE Mouse anti-human CD11b
8920049	APC Mouse anti-human CD11b
8920050	PE Mouse anti-human CD11c
8920053	PE Mouse anti-human CD13
8920054	PE-Cyanine 7 Mouse anti-human CD13
8920064	FITC Mouse anti-human CD16
8920070	FITC Mouse anti-human CD20
8920084	PE Mouse anti-human CD25
8920085	APC Mouse anti-human CD25
8920086	PE-Cyanine 7 Mouse anti-human CD25
8920100	PE Mouse anti-human CD34
8920108	FITC Mouse anti-human CD38
8920109	PE Mouse anti-human CD38
8920119	PE Mouse anti-human CD64
8920120	FITC Mouse anti-human CD71
8920123	PE Mouse anti-human CD79a
8920130	PE Mouse anti-human CD117
8920132	PE-Cyanine 7 Mouse anti-human CD117
8920140	APC Mouse anti-human CD138
8920144	APC Mouse anti-human HLA-DR
8920158	FITC Mouse anti-human ZAP-70
8920200	PE Mouse anti-human CD5
8920216	APC-Cyanine 7 Mouse anti-human HLA-DR
8920230	APC Mouse anti-human CD5
	APC Mouse anti-human CD61
8920248 8920249	FITC Mouse anti-human CD15
8920255	PE Mouse anti-human CD22
8920261	FITC Mouse anti-human MPO
8920262	APC Mouse anti-human CD79a
8920263	PE-Cyanine 7 Mouse anti-human CD3
8920264	APC-Cyanine 7 Mouse anti-human CD45
8920265	APC-Cyanine 7 Mouse anti-human CD8
8920266	PE-Cyanine 7 Mouse anti-human CD23
8920267	APC-Cyanine 7 Mouse anti-human CD36
8920268	APC-Cyanine 7 Mouse anti-human CD38
8920269	PE-Cyanine 7 Mouse anti-human CD45RA
8920270	PE Mouse anti-human CD45RO
8920271	APC Mouse anti-human CD45RO
8920272	FITC Mouse anti-human CD62P
8920273	PE Mouse anti-human CD69
8920274	PE Mouse anti-human CD127
	FITC Mouse anti-human CD14
8920276	
8920277	APC Mouse anti-human CD14
8920278	APC Mouse anti-human CD56
8920279	APC-Cyanine 7 Mouse anti-human CD56
8920280	PE-Cyanine 7 Mouse anti-human CD33
8920282	APC Mouse anti-human CD33
8920331	PE-Cyanine 7 Mouse anti-human CD11c
8920959	FITC Mouse anti-human CD45RA
8921013	PerCP-Cyanine 5.5 Mouse anit-human CD45

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8921014	FITC Mouse anti-human CD45
8921015	PerCP-Cyanine 5.5 Mouse anti-CD3
8921016	FITC Mouse anti-human CD3
8921017	PerCP Mouse anti-human CD45
	FITC Mouse anti-human CD4
8921018	
8921019	APC Mouse anti-human CD4
8921020	PE-Cyanine 7 Mouse anti-human CD4
8921021	PE Mouse anti-human CD4
8921022	PE Mouse anti-human CD8
8921023	FITC Mouse anti-human CD8
8921024	PE-Cyanine 7 Mouse anti-human CD8
8921025	APC Mouse anti-human CD8
8921029	APC-Cyanine7 Mouse anti-human CD2
8921030	PerCP-Cyanine5.5 Mouse anti-human CD33
	APC-Fire [™] 750 Mouse anti-human CD117
8921031	
8921032	APC-Fire™750 Mouse anti-human HLA-DR
8921033	APC-Fire™750 Mouse anti-human CD3
8921034	PerCP-Cyanine5.5 Mouse anti-human CD4
8921035	PE-Cyanine7 Mouse anti-human CD7
8921036	APC-Fire™750 Mouse anti-human CD10
8921037	APC Mouse anti-human CD13
8921042	PE Mouse anti-human CD23
8921043	APC Mouse anti-human CD36
8921044	PE-Cyanine 7 Mouse anti-human CD56
8921045	PE-Dazzle™594 Mouse anti-human CD56
8929995	PE Mouse anti-human CD59
8929996	FITC Mouse anti-human CD14
8929997	PE Mouse anti-human CD64
8929998	PerCP Mouse anti-human CD45
8929999	APC Mouse anti-human HLA-DR
8930007	APC Mouse anti-human CD19
8930012	CD4/CD8/CD3 mouse anti-human
8930015	PE-Cyanine 7 Mouse anti-human CD19
8930016	FITC Mouse anti-human CD19
	PE Mouse anti-human CD19
8930017	. —
8930018	PE Mouse anti-human CD1a
8930022	FITC Mouse anti-human CD2
8930023	PE Mouse anti-human CD2
8930036	PE Mouse anti-human CD7
8930043	FITC Mouse anti-human CD10
8930045	APC Mouse anti-human CD10
8930048	PE Mouse anti-human CD11b
8930049	APC Mouse anti-human CD11b
8930050	PE Mouse anti-human CD11c
8930053	PE Mouse anti-human CD13
	. —
8930054	PE-Cyanine 7 Mouse anti-human CD13
8930064	FITC Mouse anti-human CD16
8930084	PE Mouse anti-human CD25
8930085	APC Mouse anti-human CD25
8930086	PE-Cyanine 7 Mouse anti-human CD25
8930108	FITC Mouse anti-human CD38
8930109	PE Mouse anti-human CD38
8930114	APC Mouse anti-human CD56
8930119	PE Mouse anti-human CD64
8930120	FITC Mouse anti-human CD71
8930123	PE Mouse anti-human CD79a
8930130	PE Mouse anti-human CD117
8930132	PE-Cyanine 7 Mouse anti-human CD117
8930144	APC Mouse anti-human HLA-DR
8930158	FITC Mouse anti-human ZAP-70
8930200	PE Mouse anti-human CD5
8930216	APC-Cyanine 7 Mouse anti-human HLA-DR
0930210	A G-Gyanine i widuse anti-numan nilA-DK

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8930230	APC Mouse anti-human CD5
8930248	APC Mouse anti-human CD61
8930249	FITC Mouse anti-human CD15
8930261	FITC Mouse anti-human MPO
8930262	APC Mouse anti-human CD79a
8930263	PE-Cyanine 7 Mouse anti-human CD3
8930264	APC-Cyanine 7 Mouse anti-human CD45
8930265	APC-Cyanine 7 Mouse anti-human CD8
8930266	PE-Cyanine 7 Mouse anti-human CD23
8930267	APC-Cyanine 7 Mouse anti-human CD36
8930268	APC-Cyanine 7 Mouse anti-human CD38
8930269	PE-Cyanine 7 Mouse anti-human CD45RA
8930270	PE Mouse anti-human CD45RO
8930271	APC Mouse anti-human CD45RO
8930272	FITC Mouse anti-human CD62P
8930273	PE Mouse anti-human CD69
8930274	PE Mouse anti-human CD127
	. —
8930276	FITC Mouse anti-human CD14
8930277	APC Mouse anti-human CD14
8930278	APC Mouse anti-human CD56
8930279	APC-Cyanine 7 Mouse anti-human CD56
8930280	PE-Cyanine 7 Mouse anti-human CD33
8930282	APC Mouse anti-human CD33
8930331	PE-Cyanine 7 Mouse anti-human CD11c
8930959	FITC Mouse anti-human CD45RA
8931013	PerCP-Cyanine 5.5 Mouse anit-human CD45
8931014	FITC Mouse anti-human CD45
8931015	PerCP-Cyanine 5.5 Mouse anti-human-CD3
8931016	FITC Mouse anti-human CD3
8931017	PerCP Mouse anti-human CD45
8931018	FITC Mouse anti-human CD4
	APC Mouse anti-human CD4
8931019	
8931020	PE-Cyanine 7 Mouse anti-human CD4
8931021	PE Mouse anti-human CD4
8931022	PE Mouse anti-human CD8
8931023	FITC Mouse anti-human CD8
8931024	PE-Cyanine 7 Mouse anti-human CD8
8931025	APC Mouse anti-human CD8
8931029	APC-Cyanine7 Mouse anti-human CD2
8931030	PerCP-Cyanine5.5 Mouse anti-human CD33
8931031	APC-Fire [™] 750 Mouse anti-human CD117
8931032	APC-Fire™750 Mouse anti-human HLA-DR
8931033	APC-Fire™750 Mouse anti-human CD3
8931034	PerCP-Cyanine5.5 Mouse anti-human CD4
8931035	PE-Cyanine7 Mouse anti-human CD7
8931036	APC-Fire [™] 750 Mouse anti-human CD10
8931037	APC Mouse anti-human CD13
8931042	PE Mouse anti-human CD23
8931043	APC Mouse anti-human CD36
8931044	PE-Cyanine 7 Mouse anti-human CD56
8931044	PE-Dazzle [™] 594 Mouse anti-human CD56
	PE Mouse anti-human CD59
8939995	
8939996	FITC Mouse anti-human CD14
8939997	PE Mouse anti-human CD64
8939998	PerCP Mouse anti-human CD45
8939999	APC Mouse anti-human HLA-DR
8921066	PE-Cyanine7 Mouse anti-human CD28
8921067	PE-Cyanine5 Mouse anti-human CD28
8921068	APC-Cyanine7 Mouse anti-human CD28
8920698	PE-Cyanine7 Mouse anti-human CD41
8920185	FITC Mouse anti-human CD41
8931066	PE-Cyanine7 Mouse anti-human CD28
	•

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 4/17

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8931067	PE-Cyanine5 Mouse anti-human CD28
8931068	APC-Cyanine7 Mouse anti-human CD28
8930698	PE-Cyanine7 Mouse anti-human CD41
8930185	FITC Mouse anti-human CD41
8921054	APC-Cyanine7 Mouse anti-human CD13
8931054	APC-Cyanine7 Mouse anti-human CD13
8921050	PE-Cyanine5 Mouse anti-human CD7
8931050	PE-Cyanine5 Mouse anti-human CD7
8921049	PE-Cyanine5 Mouse anti-human CD10
8931049	PE-Cyanine5 Mouse anti-human CD10
8920037	APC Mouse anti-human CD7
8930037	APC Mouse anti-human CD7
8920114	APC Mouse anti-human CD56
8920702	APC-Cyanine7 Mouse anti-human CD42b
8920705	PE Mouse anti-human CD42b
8920796	APC Mouse anti-human CD58
8921051	PerCP-Cyanine5.5 Mouse anti-human CD71
8930702	APC-Cyanine7 Mouse anti-human CD42b
8930705	PE Mouse anti-human CD42b
8930796	APC Mouse anti-human CD58 PerCP Cycning 5 5 Mouse anti-human CD71
8931051 8920005	PerCP-Cyanine5.5 Mouse anti-human CD71 PE Mouse anti-human CD16
8930005	PE Mouse anti-human CD16
8921057	PE -Cyanine5 Mouse anti-human CD56
8931057	PE -Cyanines Mouse anti-human CD56
8920161	PE Mouse IgG1
8930161	PE Mouse IgG1
8920091	APC Mouse anti-human CD27
8930091	APC Mouse anti-human CD27
8920567	APC-FireTM750 Mouse anti-human CD27
8930567	APC-FireTM750 Mouse anti-human CD27
8920092	PerCP-Cyanine5.5 Mouse anti-human CD27
8930092	PerCP-Cyanine5.5 Mouse anti-human CD27
8920012CE	TrioTest CD4 FITC /CD8 PE/CD3 PerCP Kit
8930012CE	TrioTest CD4 FITC /CD8 PE/CD3 PerCP Kit
8921017CE	
8931017CE	
8921016CE	,
8931016CE	
8921034CE	
8931034CE	
8921025CE	· · · · · · · · · · · · · · · · · · ·
8931025CE	· · · · · · · · · · · · · · · · · · ·
8921015CE	
8931015CE	
8921019CE	· · · · · · · · · · · · · · · · · · ·
8931019CE 8921020CE	· · · · · · · · · · · · · · · · · · ·
8931020CE	· · · · · · · · · · · · · · · · · · ·
8921024CE	· · · · · · · · · · · · · · · · · · ·
8931024CE	
8921023CE	
8931023CE	
8920045CE	
8930045CE	
8920015CE	
8930015CE	•
8920007CE	•
8930007CE	Monoclonal Mouse anti-human CD19/APC, Clone HIB19
8920016CE	
8930016CE	· · · · · · · · · · · · · · · · · · ·
8920017CE	Monoclonal Mouse anti-human CD19/PE, Clone HIB19

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 5/17

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8930017CE	Monoclonal Mouse anti-human CD19/PE, Clone HIB19
8920070CE	Monoclonal Mouse anti-human CD20/FITC, Clone 2H7
8921091CE	Monoclonal Mouse anti-human CD34/PE, Clone 581
8921014CE	Monoclonal Mouse anti-human CD45/FITC, Clone HI30
8931014CE	Monoclonal Mouse anti-human CD45/FITC, Clone HI30
8920144CE	Monoclonal Mouse anti-human HLA-DR/APC, Clone L243
8930144CE	Monoclonal Mouse anti-human HLA-DR/APC, Clone L243
8920263CE	Monoclonal Mouse Anti-Human CD3/PE-Cyanine7, Clone UCHT1
8930263CE	Monoclonal Mouse Anti-Human CD3/PE-Cyanine7, Clone UCHT1
8921033CE	Monoclonal Mouse Anti-Human CD3/APC-Fire™750, Clone SK7
8931033CE	Monoclonal Mouse Anti-Human CD3/APC-Fire™750, Clone SK7
8920265CE	Monoclonal Mouse Anti-Human CD8/APC-Cyanine7, Clone SK1
8921036CE	Monoclonal Mouse Anti-Human CD10/APC-Fire™750, Clone HI10a
8931036CE	Monoclonal Mouse Anti-Human CD10/APC-Fire™750, Clone H110a
8930265CE	Monoclonal Mouse Anti-Human CD8/APC-Cyanine7, Clone SK1
8921049CE	Monoclonal Mouse Anti-Human CD10/PE-Cyanine5, Clone HI10a
8931049CE	Monoclonal Mouse Anti-Human CD10/PE-Cyanine5, Clone HI10a
8920264CE	Monoclonal Mouse Anti-Human CD45/APC-Cyanine7, Clone HI30 Monoclonal Mouse Anti-Human CD45/APC-Cyanine7, Clone HI30
8930264CE	
8921013CE	Monoclonal Mouse Anti-Human CD45/PerCP-Cyanine5.5, Clone HI30
8931013CE	Monoclonal Mouse Anti-Human CD45/PerCP-Cyanine5.5, Clone HI30
8920216CE	Monoclonal Mouse Anti-Human HLA-DR/APC-Cyanine7, Clone L243
8930216CE	Monoclonal Mouse Anti-Human HLA-DR/APC-Cyanine7, Clone L243
8921032CE	Monoclonal Mouse Anti-Human HLA-DR/APC-Fire™750, Clone L243
8931032CE	Monoclonal Mouse Anti-Human HLA-DR/APC-Fire™750, Clone L243
8920266CE	Monoclonal Mouse Anti-Human CD23/PE-Cyanine7, Clone EBVCS-5
8930266CE	Monoclonal Mouse Anti-Human CD23/PE-Cyanine7, Clone EBVCS-5
8920268CE	Monoclonal Mouse Anti-Human CD38/APC-Cyanine7, Clone HB-7
8930268CE	Monoclonal Mouse Anti-Human CD38/APC-Cyanine7, Clone HB-7
8920132CE	Monoclonal Mouse Anti-Human CD117/PE-Cyanine7, Clone 104D2
8930132CE	Monoclonal Mouse Anti-Human CD117/PE-Cyanine7, Clone 104D2
8921035CE	Monoclonal Mouse Anti-Human CD7/PE-Cyanine7, Clone CD7-6B7
8931035CE	Monoclonal Mouse Anti-Human CD7/PE-Cyanine7, Clone CD7-6B7
8920037CE	Monoclonal Mouse Anti-Human CD7/APC, Clone CD7-6B7
8930037CE	Monoclonal Mouse Anti-Human CD7/APC, Clone CD7-6B7
8920277CE	Monoclonal Mouse Anti-Human CD14/APC, Clone M5E2
8930277CE	Monoclonal Mouse Anti-Human CD14/APC, Clone M5E2
8920085CE	Monoclonal Mouse Anti-Human CD25/APC, Clone M-A251
8930085CE	Monoclonal Mouse Anti-Human CD25/APC, Clone M-A251
8920086CE	Monoclonal Mouse Anti-Human CD25/PE-Cyanine7, Clone M-A251
8930086CE	Monoclonal Mouse Anti-Human CD25/PE-Cyanine7, Clone M-A251
8921068CE	Monoclonal Mouse Anti-Human CD28/APC-Cyanine7, Clone CD28.2
8931068CE	Monoclonal Mouse Anti-Human CD28/APC-Cyanine7, Clone CD28.2
8921067CE	Monoclonal Mouse Anti-Human CD28/PE-Cyanine5, Clone CD28.2
8931067CE	Monoclonal Mouse Anti-Human CD28/PE-Cyanine5, Clone CD28.2
8921066CE	Monoclonal Mouse Anti-Human CD28/PE-Cyanine7, Clone CD28.2
8931066CE	Monoclonal Mouse Anti-Human CD28/PE-Cyanine7, Clone CD28.2
8920698CE	Monoclonal Mouse Anti-Human CD41/PE-Cyanine7, Clone HIP8
8930698CE	Monoclonal Mouse Anti-Human CD41/PE-Cyanine7, Clone HIP8
8920959CE	Monoclonal Mouse Anti-Human CD45RA/FITC, Clone HI100
8930959CE	Monoclonal Mouse Anti-Human CD45RA/FITC, Clone HI100
8920269CE	Monoclonal Mouse Anti-Human CD45RA/PE-Cyanine7, Clone HI100
8930269CE	Monoclonal Mouse Anti-Human CD45RA/PE-Cyanine7, Clone HI100
8920270CE	Monoclonal Mouse Anti-Human CD45R0/PE, Clone UCHL1
8930270CE	Monoclonal Mouse Anti-Human CD45R0/PE, Clone UCHL1
8920271CE	Monoclonal Mouse Anti-Human CD45R0/APC, Clone UCHL1
8930271CE	Monoclonal Mouse Anti-Human CD45R0/APC, Clone UCHL1
8920278CE	Monoclonal Mouse Anti-Human CD56/APC, Clone 5.1H11
8930278CE	Monoclonal Mouse Anti-Human CD56/APC, Clone 5.1H11
8920279CE	Monoclonal Mouse Anti-Human CD56/APC-Cyanine7, Clone 5.1H11
8930279CE	Monoclonal Mouse Anti-Human CD56/APC-Cyanine7, Clone 5.1H11
8921044CE	Monoclonal Mouse Anti-Human CD56/PE-Cyanine7, Clone 5.1H11

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 6/17

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8931044CE	Monoclonal Mouse Anti-Human CD56/PE-Cyanine7, Clone 5.1H11
8921045CE	Monoclonal Mouse Anti-Human CD56/PE-Dazzle™594, Clone 5.1H11
8931045CE	Monoclonal Mouse Anti-Human CD56/PE-Dazzle™594, Clone 5.1H11
8920273CE	Monoclonal Mouse Anti-Human CD69/PE, Clone FN50
8930273CE	Monoclonal Mouse Anti-Human CD69/PE, Clone FN50
8920262CE	Monoclonal Mouse Anti-Human CD79a/APC, Clone HM47
8930262CE	Monoclonal Mouse Anti-Human CD79a/APC, Clone HM47
8920123CE	Monoclonal Mouse Anti-Human CD79a/PE, Clone HM47
8930123CE	Monoclonal Mouse Anti-Human CD79a/PE, Clone HM47
8921031CE	Monoclonal Mouse Anti-Human CD117/APC-Fire™750, Clone 104D2
8931031CE	Monoclonal Mouse Anti-Human CD117/APC-Fire™750, Clone 104D2
8920274CE	Monoclonal Mouse Anti-Human CD127/PE, Clone A019D5
8930274CE	Monoclonal Mouse Anti-Human CD127/PE, Clone A019D5
8929988	PerCP-Cyanine5.5 Mouse anti-human CD3
8939988	PerCP-Cyanine5.5 Mouse anti-human CD3
8929989	FITC Mouse anti-human CD4
8939989	FITC Mouse anti-human CD4
8929990	APC Mouse anti-human CD25
8939990	APC Mouse anti-human CD25
8929991	PE Mouse anti-human CD127
8939991	PE Mouse anti-human CD127
8929992	PE Mouse anti-human CD69
8939992	PE Mouse anti-human CD69
8929993	FITC Mouse anti-human HLA-DR
8939993	FITC Mouse anti-human HLA-DR
8921073	Pacific Blue™ Mouse anti-human CD45
8931073	Pacific Blue™ Mouse anti-human CD45
8920142	FITC Mouse anti-human HLA-DR
8930142	FITC Mouse anti-human HLA-DR
8920034	PerCP-Cyanine5.5 Mouse anti-human CD5
8930034	PerCP-Cyanine5.5 Mouse anti-human CD5
8920046	PE-Cyanine7 Mouse anti-human CD10
8930046	PE-Cyanine7 Mouse anti-human CD10
8921074	APC-Cyanine7 Mouse anti-human CD14
8931074	APC-Cyanine7 Mouse anti-human CD14

Uses advised against : None known.

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Deutschland GmbH Hewlett-Packard-Str. 8 76337 Waldbronn Germany 0800 603 1000

e-mail address of person : pdl-msds_author@agilent.com

responsible for this SDS

1.4 Emergency telephone number

Emergency telephone : CHEMTREC®: +(44)-870-8200418 number (with hours of

operation)

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 7/17

Antibodies Reagent IVD

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word No signal word.

: No known significant effects or critical hazards. **Hazard statements**

Precautionary statements

Prevention : Not applicable. Response : Not applicable. **Storage** : Not applicable. **Disposal** : Not applicable. Supplemental label : Not applicable.

elements

Annex XVII - Restrictions : Not applicable.

on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Special packaging requirements

Tactile warning of

danger

: Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB

according to Regulation (EC) No. 1907/2006, Annex XIII

Other hazards which do

not result in classification : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eve contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower

eyelids. Check for and remove any contact lenses. Get medical attention if irritation

occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get

medical attention if symptoms occur.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and

shoes. Get medical attention if symptoms occur.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 8/17

Antibodies Reagent IVD

SECTION 4: First aid measures

Wash out mouth with water. If material has been swallowed and the exposed person is Ingestion

conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

: No specific data. **Eye contact** Inhalation : No specific data. **Skin contact** : No specific data. : No specific data. Ingestion

4.3 Indication of any immediate medical attention and special treatment needed

: Treat symptomatically. Contact poison treatment specialist immediately if large Notes to physician

quantities have been ingested or inhaled.

Specific treatments No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing

media

: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing

media

: None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous combustion

products

: No specific data.

5.3 Advice for firefighters

Special precautions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable

Special protective equipment for firefighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

incidents.

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 9/17

Antibodies Reagent IVD

SECTION 6: Accidental release measures

For emergency responders

: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Storage

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations: Industrial applications, Professional applications.

Industrial sector specific : Not available.

solutions

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

No exposure limit value known.

Biological exposure indices

No exposure indices known.

Recommended monitoring procedures

: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 10/17

SECTION 8: Exposure controls/personal protection

agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

No DNELs/DMELs available.

PNECs

No PNECs available

8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

Skin protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid.

Colour Not available. **Odour** : Not available. **Odour threshold** : Not available.

Melting point/freezing

point

Initial boiling point and

boiling range

: 0°C

: 100°C

Flammability : Not applicable.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2

Antibodies Reagent IVD

SECTION 9: Physical and chemical properties

Upper/lower flammability: Not available.

or explosive limits

Flash point **Auto-ignition** temperature

: Not available. : Not available.

Decomposition

: Not available.

temperature

pН Not available Not available. **Viscosity**

Solubility(ies) Media

Result water Soluble

Miscible with water

Yes.

Partition coefficient: n-

: Not applicable.

octanol/water

Vapour pressure

	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3	-	92.258	12.3	-

Evaporation rate : Not available. **Relative density** : Not available. Vapour density : Not available. **Explosive properties** : Not available. : Not available. **Oxidising properties**

Particle characteristics

Median particle size : Not applicable.

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

: No specific test data related to reactivity available for this product or its ingredients. 10.1 Reactivity

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials

: May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

: 4.2 Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version 12/17

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Not available.

Acute toxicity estimates

N/A

Irritation/Corrosion

Conclusion/Summary: Not available.

Sensitiser

Conclusion/Summary: Not available.

Mutagenicity

Conclusion/Summary: Not available.

Carcinogenicity

Conclusion/Summary: Not available.

Reproductive toxicity

Conclusion/Summary: Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely : Not available.

routes of exposure

Potential acute health effects

Inhalation : No known significant effects or critical hazards.
 Ingestion : No known significant effects or critical hazards.
 Skin contact : No known significant effects or critical hazards.
 Eye contact : No known significant effects or critical hazards.
 Symptoms related to the physical, chemical and toxicological characteristics

Inhalation: No specific data.Ingestion: No specific data.Skin contact: No specific data.Eye contact: No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate : Not available.

effects

Potential delayed : Not available.

effects

Long term exposure

Potential immediate : Not available.

effects

Potential delayed : Not available.

effects

Potential chronic health effects

Conclusion/Summary: Not available.

Date of issue/Date of revision: 20/09/2023Date of previous issue: 28/11/2022Version: 4.2

Antibodies Reagent IVD

SECTION 11: Toxicological information

General : No known significant effects or critical hazards.
 Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Conclusion/Summary: Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 14/17

SECTION 13: Disposal considerations

Special precautions

: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-
14.5 Environmental hazards	No.	No.	No.

Additional information

14.6 Special precautions for user

: **Transport within user's premises**: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

Label : Not applicable.

Other EU regulations

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 15/17

Antibodies Reagent IVD

SECTION 15: Regulatory information

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia : Not determined.

Canada : Not determined.

China : All components are listed or exempted.

Eurasian Economic

Union Japan : Russian Federation inventory: Not determined.

: Japan inventory (CSCL): Not determined.

New ZealandJapan inventory (ISHL): Not determined.

Not determined.

Philippines : Not determined.

Republic of Korea : Not determined.

Taiwan : All components are listed or exempted.

Thailand : Not determined.

Turkey : Not determined.

United States : All components are active or exempted.

Viet Nam : Not determined.

15.2 Chemical safety

assessment

: This product contains substances for which Chemical Safety Assessments might still

be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

Full text of abbreviated H statements

Not applicable.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 16/17

Antibodies Reagent IVD

SECTION 16: Other information

Full text of classifications [CLP/GHS]

Not applicable.

Date of issue/ Date of : 20/09/2023

revision

Date of previous issue : 28/11/2022

Version : 4.2

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.

Date of issue/Date of revision : 20/09/2023 Date of previous issue : 28/11/2022 Version : 4.2 17/17